PPARG and early-onset autosomal dominant Alzheimer disease: Peroxisome proliferator-activated receptor-gamma (PPARγ) agonists such as rosiglitazone and pioglitazone have shown promising therapeutic potential against Alzheimer's disease (AD) in preclinical studies1, 2, 3, 4, 5.